Our portfolio

Low-cost tech for anti-malaria treatments

Amyris develops new, low-cost technologies for manufacturing compounds to make semi-synthetic artemisinin, which can be used in anti-malaria treatments.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Active
  • Initial investment
    Public
  • Partnered in
    2016
  • Investment lead
    Ryan Kreitzer
  • Headquarters
    USA
  • Program strategy
    Malaria

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.